The last two years have represented significant growth in many ways for CURE Childhood Cancer. Under Ken Biggerstaff’s leadership as President of the Board of Directors for the past two years, CURE has achieved many accomplishments. Here is a sampling:
• Achieving 12% growth in fundraising from $1.7 million to $1.95 million, allowing CURE to increase funding of critical research.
• Funding of six specific research projects covering neuroblastoma, leukemia and brain tumors.
• Reaching 75% of newly diagnosed patients and their families in Georgia through our Early Outreach Program.
• Assisting 224 families with emergency financial assistance through our Family Emergency Fund.
• Adding eight new members to the Board of Directors.
• Strengthening our CURE staff to add important expertise to accomplish our mission.
Please join me in saluting the contributions that Ken has made during the past two years and throughout his 11-year relationship with CURE. We look forward to his continuing support and guidance in the fight to cure childhood cancer.
On behalf of all CURE Board members, I would also like to congratulate our Executive Director, Kristin Connor, who serves as our day-to-day leader. Her personal commitment, unending energy and leadership have built the foundation for CURE’s ongoing and future success toward curing childhood cancer. She has earned the respect and admiration of the Board, her team and the greater CURE community. Her contributions are a key reason that CURE has been and will continue to be successful.
Each of you reading our newsletter has a vested interest in finding a cure for a disease that devastates our children and their families. Your trust and confidence in CURE’s mission also cannot go unrecognized. Thank you all for your support – through your donations, your time, and your guidance. And thank you for spreading the word about CURE’s vision and mission.
NEW FISCAL YEAR
Our fiscal year ended in June and as noted above, we had an excellent year – especially considering the recessionary economy. Regardless of what’s happening in the economy, though, childhood cancer never abates. CURE’s effort to fund a cure, therefore, cannot abate.
This past spring, the Board of Directors developed and approved a strategic plan to guide CURE over the next three-to-five years. CURE’s strategic plan builds on the key strengths of the organization and sets new goals to take CURE ever closer to our vision and ultimate mission.
We believe strongly that our mission must balance two critical objectives: 1) funding significant and impactful research on one side; and 2) helping patients and their families throughout their journey with childhood cancer on the other.
On the research side, we invest in the stellar childhood cancer research programs at the Aflac Cancer Center of Children’s Healthcare of Atlanta and Emory University. As noted earlier, we funded six research programs last year and will continue to support like programs in the coming year. Our patient and family support programs will also continue in earnest
You will receive shortly the CURE Annual Report where we will outline last year’s accomplishments and our plans for the coming year. Thank you for investing in CURE.
For the children with cancer,
Don Campbell, President; CURE Childhood Cancer Board of Directors
For more information on CURE, visit us at www.curechildhoodcancer.org